Home / Posts Tagged "Venus Medicine Research Centre"

Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian exporter of generic drugs, has received marketing authorization from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in

READ MORE

Commitment to stringent European standards reinforces Venus Remedies’ leadership in antibiotics and oncology manufacturing while positioning the company for continued growth in global markets  Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a premier player in the global pharmaceutical industry, has announced the successful renewal of its

READ MORE

Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026  Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading global pharmaceutical company, has achieved a significant milestone by receiving Good Manufacturing Practices (GMP) certification from

READ MORE

This key accreditation opens doors to expanded global business opportunities by enabling quicker approvals in other PIC/S member countries. Venus Remedies Limited, a leading exporter of affordable generic drugs with presence in more than 80 countries, has achieved a major regulatory milestone by receiving Good Manufacturing

READ MORE

Mr Himanshu Baid, Managing Director, Poly Medicure Ltd. Union Budget 2024: Strengthening Healthcare for a Resilient India We welcome the Union Budget's focus on healthcare, which marks a pivotal step towards enhancing healthcare accessibility and quality in India. Finance Minister's proposed changes in customs duty aimed at synchronizing

READ MORE

The disbursement will bolster the company’s manufacturing capabilities and foster product diversification, including complex generics The grant emphasises the company’s commitment to driving innovation, entitles it to incentives for incremental sales of eligible pharmaceutical products   Venus Remedies Ltd, one of India’s leading manufacturers of generic

READ MORE

This GMP certification for the company’s production facilities has added to its portfolio of international approvals from 25 regulators The recognition demonstrates Venus Remedies’ persistence in adhering to stringent manufacturing standards and providing greater access to life-saving drugs in the African continent   Venus Remedies, a

READ MORE

Venus Remedies has secured regulatory approval from Philippines for chemotherapy medication paclitaxel and zoledronic acid, a drug used to treat metabolic bone disorders The company has also received marketing authorisation for another chemotherapy drug, bleomycin, from Saudi Arabia While Saudi Arabia is the largest

READ MORE

The $4.20-billion pharmaceutical market of the Philippines accounts for a significant market for Venus Remedies from the ASEAN region as the company moves a step closer towards emerging as the top oncology medicine supplier from India in Southeast Asia  Venus Remedies’ oncology wing has

READ MORE